Glucagon-Like Peptide-1 Inhibits Prandial Gastrointestinal Motility Through Myenteric Neuronal Mechanisms in Humans.

What Was Tested

This clinical trial looks at Glucagon.

Investigate whether physiological plasma concentrations of GLP-1 inhibit human postprandial motility and determine mechanism of action of GLP-1 and analog ROSE-010 action.

Why It Was Studied

Glucagon-like peptide-1 (GLP-1) secretion from l-cells and postprandial inhibition of gastrointestinal motility.

Who Took Part

The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, men only.

Healthy volunteers investigated with antroduodenal manometry.

How the Study Was Run

In design terms this was a single-blind and parallel-group study.

Only one side, usually the participants, was kept unaware of whether Glucagon was given.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Human gastric and intestinal muscle strips.

Motility indices (MIs) obtained before and during GLP-1 or saline infusion.

Plasma GLP-1 and glucagon-like peptide-2 (GLP-2) measured by radioimmunoassay.

Gastrointestinal muscle strips investigated for GLP-1- and ROSE-010-induced relaxation employing GLP-1 and GLP-2 and their receptor localization, and blockers exendin(9-39)amide, Lω-nitro-monomethylarginine (L-NMMA), 2',5'-dideoxyadenosine (DDA), and tetrodotoxin (TTX) to reveal target mechanism of GLP-1 action.

What Was Measured

Glucagon-like peptide-1 (GLP-1) secretion from l-cells and postprandial inhibition of gastrointestinal motility.

PubMed files the paper under topics including Duodenum, Gastric Emptying, Gastrointestinal Motility, Glucagon-Like Peptide 1, Healthy Volunteers, Manometry and Myenteric Plexus.

What This Means in Plain Language

The paper is a single-blind and parallel-group study of Glucagon.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Glucagon compound page, all human trials.